Eli Lilly has received the permission for the drug for restricted emergency use from Central Drugs Standard Control Organization, a division of the Ministry of Health.
Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of COVID-19 in India. The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company.
Recommended ArticlesView All
Withering Weather: Experts see erratic rains to spell higher food prices and tougher inflation ahead
Mar 24, 2023 IST4 Min(s) Read
Decoding Finance Bill proposals for debt funds: What remains and what changes
Mar 24, 2023 IST3 Min(s) Read
World TB Day: These key challenges could certainly fail India's TB elimination goal
Mar 24, 2023 IST6 Min(s) Read
Desk-bombing and more — why Gen Z loves going to office
Mar 23, 2023 IST4 Min(s) Read
Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Eli Lilly has received the permission for the drug for restricted emergency use from Central Drugs Standard Control Organization, a division of the Ministry of Health. Baricitinib is an oral medication currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
”We hope this collaboration will address more unmet medical needs by broadening and deepening the discovery and development of COVID-19 treatments options,” BDR Pharmaceuticals Chairman Dharmesh Shah said in a statement. BDR has applied for restricted emergency use approval with the Drug Controller General of India (DCGI) for baricitinib for COVID-19 in India. Lilly has already announced seven voluntary license agreements with major local generic drug manufacturers in India for the production of the same.
Lilly is committed to supporting India in this healthcare challenge through our innovative and effective portfolio of breakthrough medicines. We are swiftly working to ensure high-quality manufacturing and equitable access of Baricitinib for COVID-19 in India. We will continue to explore other possible initiatives to support patients and the healthcare system in India, Lilly India Managing Director (India Subcontinent) Luca Visini said.
First Published: May 19, 2021 1:45 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!